Navigation Links
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In OvaScience, Inc. To Contact The Firm
Date:9/20/2013

NEW YORK, Sept. 20, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS).

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies.

Specifically, the investigation focuses on whether OvaScience misrepresented to the FDA and the investing public that its AUGMENT technology qualified for 361 HCT/P designation and therefore did not need FDA licensure in order to be tested and marketed.

On September 10, 2013, the Company announced that it would suspend enrollment of AUGMENT in the U.S. after receiving an "untitled" letter from the FDA questioning the designation of AUGMENT as 361 HCT/P. 

Following this news, OvaScience's stock declined by $3.32 or over 23%.

Request more information now by clicking here:  www.faruqilaw.com/OVAS.  There is no cost or obligation to you.

Take Action

If you invested in OvaScience stock or options between February 25, 2013 and September 10, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/OVAS.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neptune Technologies & Bioressources Inc. To Contact The Firm
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
7. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
8. Fifth Cycle of Probiotics & Microbiota Research Grant Announced
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
11. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV), a precision medicine ... Bill Welch , will be presenting at this ... AM EDT at the Essex House in ... Scientific Officer, Mark Erlander , Ph.D., will also ... The presentation will be webcast live at ...
(Date:3/27/2017)... 2017 Neurotrope, Inc. (OTCQB: NTRP),  a ... diseases, including Alzheimer,s disease, today announced that it ... the Company,s common stock on the NASDAQ Capital ... Market, a unit of the NASDAQ OMX Group. ... Opening Bell at the NASDAQ MarketSite in Times ...
(Date:3/24/2017)... and ROCKVILLE, Md. , ... company of Maxwell Biotech Venture Fund (MBVF), today announced ... SQ109 added to the standard drug therapy regimen in ... new small molecule drug discovered by scientists at Sequella, ... National Institutes of Health. A total ...
(Date:3/24/2017)... BEIJING , March 24, 2017 Sinovac Biotech Ltd. ... products in China , today announced that its ... the expiration date of the plan from March 27, 2017 to ... proposal. About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is ...
Breaking Biology Technology:
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
Breaking Biology News(10 mins):